Rizatriptan
Generic name
Rizatriptan
Brand name
ATC Code
N02CC04
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No kinetic studies have been carried out in children.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Migraine: acute treatment during headache phase |
|---|
|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Risk of cardiovascular conditions including myocardial infarction.
Dizziness, dry mouth, nausea, sleepiness, asthenia.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
ANTIMIGRAINE PREPARATIONS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Selective serotonin (5HT1) agonists | ||
|---|---|---|
| N02CC01 | ||
| N02CC03 | ||
| Other antimigraine preparations | ||
|---|---|---|
| N02CX01 | ||
References
- Ahonen K et al, A randomized trial of rizatriptan in migraine attacks in children, Neurology, 2006, 67, 1135-40
- Visser WH, et al, Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies, Headache, 2004, Oct;44(9), 891-9
- Winner P, et al, Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study, Headache, 2002, Jan;42(1), 49-55
Changes
Therapeutic Drug Monitoring
Overdose
